CRVL vs MCRB vs MGRC vs NKTR vs ARWR

For growth investors, Arrowhead Pharmaceuticals, Inc.

(ARWR) is the stronger pick with 232. 6% revenue growth year-over-year, versus -43. 9% for Nektar Therapeutics (NKTR). Seres Therapeutics, Inc. (MCRB) offers the better valuation at 12. 1x trailing P/E, making it the more compelling value choice. Analysts rate Seres Therapeutics, Inc. (MCRB) a "Buy" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Seres Therapeutics, Inc.

(MCRB) is the cheapest at 12. 1x versus CorVel Corporation at 31. 7x. On forward P/E, McGrath RentCorp is actually cheaper at 17. 7x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, McGrath RentCorp (MGRC) delivered a total return of +49.

0%, compared to -98. 1% for Seres Therapeutics, Inc. (MCRB). Over 10 years, the gap is even starker: ARWR returned +1253% versus MCRB's -98. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), CorVel Corporation (CRVL) is the lower-risk stock at 0.

48β versus Nektar Therapeutics's 1. 85β — meaning NKTR is approximately 287% more volatile than CRVL relative to the S&P 500. On balance sheet safety, CorVel Corporation (CRVL) carries a lower debt/equity ratio of 9% versus 188% for Seres Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Arrowhead Pharmaceuticals, Inc.

(ARWR) is pulling ahead at 232. 6% versus -43. 9% for Nektar Therapeutics (NKTR). On earnings-per-share growth, the picture is similar: Seres Therapeutics, Inc. grew EPS 103. 4% year-over-year, compared to -32. 7% for McGrath RentCorp. Over a 3-year CAGR, ARWR leads at 50. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Seres Therapeutics, Inc.

(MCRB) is the more profitable company, earning 721. 9% net margin versus -297. 1% for Nektar Therapeutics — meaning it keeps 721. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MGRC leads at 25. 9% versus -119. 1% for MCRB. At the gross margin level — before operating expenses — NKTR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, McGrath RentCorp (MGRC) trades at 17.

7x forward P/E versus 33. 4x for CorVel Corporation — 15. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NKTR: 59. 3% to $132. 83.

In this comparison, MGRC (1.

7% yield) pays a dividend. CRVL, MCRB, NKTR, ARWR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, McGrath RentCorp (MGRC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

87), 1. 7% yield, +401. 5% 10Y return). Nektar Therapeutics (NKTR) carries a higher beta of 1. 85 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MGRC: +401. 5%, NKTR: -59. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (CRVL (Financial Services) and MCRB (Healthcare) and MGRC (Industrials) and NKTR (Healthcare) and ARWR (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: CRVL is a small-cap quality compounder stock; MCRB is a small-cap deep-value stock; MGRC is a small-cap quality compounder stock; NKTR is a small-cap quality compounder stock; ARWR is a mid-cap high-growth stock. MGRC pays a dividend while CRVL, MCRB, NKTR, ARWR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.